• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Haemonetics gains on Q4, merger news

Haemonetics gains on Q4, merger news

April 30, 2012 By MassDevice staff

Haemonetics logo

Haemonetics (NYSE:HAE) gained 3.7% in early morning trading today despite missing Wall Street’s 4th-quarter expectations and lower quarterly profits, as investors reacted to its planned $551 million buyout of Pall Corp.‘s (NYSE:PLL) blood management business.

HAE shares were going for $71.24 apiece as of about 11:30 a.m. today after the company released its Q4 earnings report and announced plans to pick up blood management business for $551 million.

"Today manual whole blood collection is a $1.2 billion global market," Haemonetics president & CEO Brian Concannon said in prepared remarks. "This acquisition is an important and exciting step toward our objective of serving that market."

"The Pall business assets provide us with leading filter technology and manufacturing capability, a broad portfolio of manual collection and processing products, a strong and experienced employee base and relationships with major blood authorities and key customers we have in common," he added. "Combined with our internal development initiatives to automate whole blood collection and our suite of blood management software, Haemonetics will represent the broadest product offering to address our customers’ needs in the whole blood market, a market with more than 60 million procedures per year."

The Braintree, Mass.-based blood management giant saw a strong uptick in sales during the 3 months ended March 31.

Haemonetics posted sales of $186.7 million during its 4th quarter, a 9.8% increase over the same period last year.

Profits, however, sank 15.2% to $17.8 million, or 69¢ earned per diluted share, compared with $21 million, or 81¢ per share, during the same quarter last year.

Excluding 1-time items, Haemonetics posted earnings of 80¢ per share, missing Wall Street’s forecast by 3¢.

"The 4th quarter performance completes a fiscal year in which we realized revenue growth every quarter," Concannon said in a statement. "As we close out fiscal 2012, we are in a very good position to succeed in all of our businesses."

Haemonetics’ 2012 sales were close to $728 million, a 7.5% increase from the $676.7 million in sales in 2011. Full-year dropped 16.4% to $66.9 million, or $2.59 per diluted share, compared with $80 million, or $3.12 per share, in 2011.

Filed Under: Blood Management, MassDevice Earnings Roundup, Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: 2012, Haemonetics, Pall Corp., Q1

More recent news

  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy